ALT Altimmune Inc

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the management team will present during a fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually on September 13-15, 2021.

Details on the H.C. Wainwright fireside chat presentation are as follows:

	Title:		H.C. Wainwright 23rd Annual Global Investment Conference
	Presenters:		Vipin Garg, Ph.D., Chief Executive Officer
			Scott Harris, M.D., Chief Medical Officer
	Date/Time:		Monday, September 13, 2021 (virtual pre-record available at 7 a.m. EST)

A webcast link to the fireside chat presentation will be accessible on the Events section of the Altimmune website.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (ALT-801), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter

Investor & Media Contacts:

Will Brown                                                        Chief Financial Officer                                                 Phone: 240-654-1450                                                        wbrown@altimmune.com